BMO Capital Markets Initiates Coverage on Regado Biosciences (RGDO)
Investment analysts at BMO Capital Markets assumed coverage on shares of Regado Biosciences (NASDAQ:RGDO) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Shares of Regado Biosciences (NASDAQ:RGDO) opened at 5.30 on Monday. Regado Biosciences has a 52 week low of $4.27 and a 52 week high of $5.38. The stock has a 50-day moving average of $4.78 and a 200-day moving average of $4.78. The company’s market cap is $108.0 million.
Separately, analysts at Canaccord Genuity initiated coverage on shares of Regado Biosciences (NASDAQ:RGDO) in a research note to investors on Monday. They set a “buy” rating and a $14.00 price target on the stock.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.